Merck & Co., Inc. (NYSE:MRK) Shares Bought by Security National Bank

Security National Bank grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,303 shares of the company’s stock after acquiring an additional 954 shares during the period. Merck & Co., Inc. comprises approximately 2.2% of Security National Bank’s holdings, making the stock its 16th biggest position. Security National Bank’s holdings in Merck & Co., Inc. were worth $4,740,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Titan Capital Management LLC CA acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $25,000. LFA Lugano Financial Advisors SA boosted its holdings in shares of Merck & Co., Inc. by 250.0% in the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after buying an additional 225 shares during the period. JJJ Advisors Inc. acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Cumberland Partners Ltd acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $40,000. Finally, Fusion Family Wealth LLC boosted its holdings in shares of Merck & Co., Inc. by 268.2% in the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after buying an additional 354 shares during the period. 74.99% of the stock is owned by institutional investors.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the sale, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.

A number of research firms have issued reports on MRK. Credit Suisse Group reissued a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Svb Leerink began coverage on shares of Merck & Co., Inc. in a research note on Friday, August 16th. They set an “outperform” rating and a $103.00 target price for the company. JPMorgan Chase & Co. set a $96.00 target price on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research note on Thursday, October 10th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $84.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, June 21st. Finally, Mizuho reissued a “buy” rating and set a $97.00 target price on shares of Merck & Co., Inc. in a research note on Sunday, September 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and sixteen have given a buy rating to the company’s stock. Merck & Co., Inc. has an average rating of “Buy” and an average target price of $94.44.

Shares of MRK stock traded down $0.37 during midday trading on Wednesday, reaching $84.67. 283,505 shares of the company were exchanged, compared to its average volume of 7,860,399. Merck & Co., Inc. has a 12 month low of $66.10 and a 12 month high of $87.35. The company has a market cap of $217.73 billion, a P/E ratio of 19.50, a PEG ratio of 1.71 and a beta of 0.53. The company’s 50 day moving average price is $84.47 and its two-hundred day moving average price is $82.29. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The company had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. During the same period in the previous year, the firm earned $1.06 EPS. Merck & Co., Inc.’s revenue was up 12.4% on a year-over-year basis. As a group, sell-side analysts predict that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, October 7th. Shareholders of record on Monday, September 16th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, September 13th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.60%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit